Prostate Cancer Ontology
Center for Systems Biology, Sichuan University West China Hospital, Sichuan China
跳过导航链接。
折叠 Prostate cancerProstate cancer
展开 Epidemiological aspects of prostate cancerEpidemiological aspects of prostate cancer
展开 Diagnostic aspects of prostate cancerDiagnostic aspects of prostate cancer
折叠 Therapeutic aspects of prostate cancerTherapeutic aspects of prostate cancer
展开 Deferred treatmentDeferred treatment
展开 SurgerySurgery
展开 RadiotherapyRadiotherapy
展开 CryotherapyCryotherapy
展开 Hormonal therapyHormonal therapy
展开 ChemotherapyChemotherapy
展开 Castration-resistant prostate cancer (CRPC)Castration-resistant prostate cancer (CRPC)
展开 Metastatic prostate cancerMetastatic prostate cancer
折叠 Other treatmentOther treatment
展开 Management of prostate cancer in older menManagement of prostate cancer in older men
展开 Options other than surgery and radiotherapy for the primary treatment of localised prostate cancerOptions other than surgery and radiotherapy for the primary treatment of localised prostate cancer
展开 Post-treatment quality of life in patients with localised prostate cancerPost-treatment quality of life in patients with localised prostate cancer
折叠 Treatment of PSA-only recurrence after treatment with curative intentTreatment of PSA-only recurrence after treatment with curative intent
Salvage brachytherapy for radiotherapy failure
Preferred Name Salvage brachytherapy for radiotherapy failure
Definition Following local recurrence after previous definitive RT there is no indication for external beam salvage RT as the total dose is limited and therefore the chance of cure is low. For carefully selected patients with primary localised PCa and histologically proven local recurrence, high- or low-dose rate (H/LDR) brachytherapy remain effective treatment options with an acceptable toxicity profile. However, the published series are relatively small, therefore this treatment should be offered in experienced centres only. Fifty-two patients were treated at the Scripps Clinic with HDR-brachytherapy over a period of nine years. With a median followup of 60 months the 5-year biochemical control was 51% and only 2% grade 3 GU toxicities were reported.Comparable with these data, 42 patients were treated in a phase-II-trial at MSCCC in New York. Ofnote, the median pre-treatment dose was 81 Gy given with IMRT and the prescription HDR-dose of 32 Gy was delivered in four fractions over 30 hours. The biochemical relapse-free survival after 5 years was 69%(median follow-up 36 months). Grade 2 late side effects were seen in 15% and one patient developed Grade 3 incontinence. However, older data with higher rates of side effects have been reported.
Synonyms & Abbreviations Salvage brachytherapy for radiotherapy failure
ReferenceCode NA
ReferenceURL NA
PMID NA
Copyright (C) 2022 Institutes for Systems Genetics, Sichuan University West China Hospital. All Rights Reserved.